Modeling and predicting clinical outcomes of antibiotic therapy

Infections in Medicine

Volumn 15, Issue 8 SUPPL. E, 1998, Pages 46-54

  Pechère, Jean Claude ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

Antibiotics; Clinical efficacy; Clinical failure; Clinical response; Microbiologic eradication; Microbiologic outcome; Minimum inhibitory concentration (MIC); Modeling

Indexed keywords

EID: 0002455997     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bartlett JG, Mundy LM: Community acquired pneumonia. N Engl J Med 333:1618-1624, 1995.
2. Douherty SH: Antimicrobial culture and susceptibility testing has little value for routine management of secondary bacterial peritonitis. Clin Infect Dis 25(suppl 2):S258-S261, 1997.
3. Mandell LA: New treatment options for pneumonia. Infect Med 15(suppl E):34-45, 1998.
4. Hill A, Bayley D, Cambell E, et al: Bronchial inflammation in patients colonised with Haemophilus parainfluenzae and non-typeable Haemophilus influenzae. Abstracts from the proceeding of the European Society of Respiratory Infection, Berlin, September 1997. Abstract S52.
5. National Committee for Clinical Laboratory Standards: Performance standards for Antimicrobial Susceptibility Testing: Eighth informational supplement: M100-S8, 1998.
6. Dagan R, Abramson O, Leibovitz E, et al: Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 176:1253-1259, 1997.
7. Gehanno P, Lenoir G, Berche P: In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media. Antimicrob Agents Chemother 39(1):271-272, 1995.
8. Hook EW III, McCormack WM, Martin D, et al: Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. Antimicrob Agents Chemother 41(8):1843-1845, 1997.
9. Holm S, Henning C, Grahn E, et al: Is penicillin the appropriate treatment for recurrent tonsillopharyngitis? Results from a comparative randomized blind study of cefuroxime axetil and phenoxymethyl penicillin in children. Scand J Infect Dis 27(3):221-228, 1995.
10. Gehanno P, Chiche D: Tonsillopharyngitis: Evaluation of short-term treatment with cefuroxime axetil versus standard 10-day penicillin V therapy. Br J Clin Pract 49(1):28-32, 1995.
11. Craig WA: Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89-96, 1995.
12. Friedland IR, McCracken GH: Management of infections caused by antibiotic resistant Streptococcus pneumoniae. N Engl J Med 331(6):377-382, 1994.
13. Davey PG, Rutherford D, Graham B, et al: Repeat consultations after antibiotic prescribing for respiratory infection: A study in one general practice. Br J Gen Pract 44:509-513, 1994.
14. Macfarlane JT, Colville A, Guion A, et al: Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 341:511-514, 1993.
15. DeAbate CA, Russell M, McElvaine P, et al: Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir Care 42(2):206-213, 1997.
16. Cazzola M, Vinciguerra A, Beghi GF, et al: Comparative evaluation of the clinical and microbiological efficacy of co-amoxiclav vs cefixime or ciprofloxacin in bacterial exacerbation of chronic bronchitis. J Chemother 7(5):432-441, 1995.
17. Beghi GF, Berni F, Carratu L, et al: Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 7(2):146-152, 1995.
18. Perez-Gonzalvo ME, Mosquera-Pestana JA, Ramos D, et al: Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis. Clin Ther 18(3):440-447, 1996.
19. Klietmann W, Cesana M, Rondel RK, et al: Double-blind, comparative study of rufloxacin once daily versus amoxicillin three times a day in treatment of outpatients with exacerbations of chronic bronchitis. Antimicrob Agents Chemother 37(11):2298-2306, 1993.
20. Ulmer W: Fleroxacin versus amoxicillin in the treatment of acute exacerbation of chronic bronchitis. Am J Med 94(suppl 3A):136S-141S, 1993.
21. Legnani D, Lombardo VM, Negretto GG, et al: Comparative clinical and microbiological study of amoxycillin-clavulanic acid and ciprofloxacin in acute purulent exacerbations of chronic bronchitis. J Hosp Infect 22(suppl A):S69-S74, 1992.
22. Gotfried MH, Ellison WT: Safety and efficacy of lomefloxacin versus cefaclor in the treatment of acute exacerbations of chronic bronchitis. Am J Med 92(suppl 4A):108S-113S, 1992.
23. Guay DR, Craft JC: Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbation of chronic bronchitis. Intern Med 231:295-301, 1992.
24. Aidons PM: A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 27(suppl A):S101-S108, 1991.
25. Fraschini F: Clinical efficacy and tolerance of two new macrolides, clarithromycin and josamycin, in the treatment of patients with acute exacerbations of chronic bronchitis. J Int Med Res 18:171-176, 1990.
26. Chodosh S: Efficacy of fleroxacin versus amoxycillin in acute exacerbations of chronic bronchitis. Am J Med 94(suppl 3A):131S-135S, 1993.
27. Saito A: Clinical breakpoints for antimicrobial agents in pulmonary infections and sepsis: Report of the Committee for Japanese Standards for antimicrobial susceptibility testing for bacteria. J Infect Chemother 1:83-88, 1995.
28. Fine MJ, Smith MA, Carson CA, et al: Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis. JAMA 275:134-141, 1996.
29. Christiansen K: Community-acquired pneumonia: Epidemiologic and clinical considerations. Clin Microbiol Infect 1(suppl 2):S23-S29, 1996.
30. Niederman MS: Community-acquired pneumonia: Defining the problem. Infect Med 15(suppl E):11-19, 1998.
31. Adams M, Sullivan J, Henry D, et al: Comparison of grepafloxacin with cefaclor in the treatment of community-acquired pneumonia. Abstracts from the proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 1997, Abstract LM68.
32. Patel T, Desai R, Duff J, et al: Comparison of grepafloxacin with clarithromycin in the treatment of community acquired pneumonia. Abstracts from the proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 1997. Abstract LM69.
33. O'Doherty B, Dutchman DA, Pettit R, et al: Randomised double blind comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia (study No. 106-92-302). J Antimicrob Chemother 40(suppl A):S73-S82, 1997.
34. Topkis S, Swarz H, Breich SA, et al: Efficacy and safety of grepafloxacin 600mg qd for 10 days in patients with community-acquired pneumonia (study No. 106-92-205). Curr Ther Res 19(5):975-988, 1997.
35. Cargill K: The cost of antimicrobial resistance. J Antimicrob Chemother. In press.